Pinned Tweet
I work in biotech R&D. But I also have a passion for biotech investing, particularly viewed through the lens of options markets.
Several years ago I started logging every biotech and pharma options trade into a personal database, mostly out of curiosity. The database is now tens of millions of trades deep, and it's become my favorite tool for understanding what's moving in the sector and why.
It also turns up some remarkable, "unusual" stories. For example, back on March 27 of this year, someone bought $11,616 of short-dated, OTM $APLS calls. Four days later, Biogen announced it was acquiring Apellis, and the value of those calls skyrocketed to $982,520 (!).
I recently started Off-Label Trades on Substack to share it all: a daily interactive report of the most interesting biotech options trades, the day's biggest winners, and occasional deeper dives on retrospective case studies like the $APLS example above.
The newsletter is free to sign up, no paywalls. Whether you are a seasoned options trader, a biotech professional, or just curious about the intersection between options trading and the highly volatile biotech and pharma sector in general, I'd love to have you follow along.
1
1
143
Replying to @ScorpionFund
At least your $SLNO report was based on actual in-human data.
What you're saying about $ABVX is late to the story wet lab speculation that has already debunked by the existing in human data which very clearly show malignancy rates within or below the expected background rates...Which even your own tables show!
BTW, you seem not to know this, but institutional investors ran these lab studies that you just did years ago already, and those same people ended up becoming some of the company's biggest bulls and current investors. I know you think you published something new here - you didn't. The AhR stuff is old old news. Years late to the story, and the in human data have already played out to $ABVX's favor.
I could go on and on listing the absurdities in this document...discussing monkey tox concerns at 500mg/kg/day (~1000x the human dose!!!), concerns over "Chinese data" when ABTECT-2 had literally ZERO Chinese trial sites.
You point out preclinical phototoxicity signals and speculate that the company didn't know or didn't do anything about it...yet enhanced skin surveillance was BUILT INTO THE STUDIES PROSPECTIVELY by the company! The company itself not only knew about this, but literally specifically designed the studies to test phototox concerns and either confirm it or rule it out....WHICH IT ULTIMATELY DID rule out.
Pointing out that the parent molecule is lipophilic and using that to call it an "agrochemical"... Just laughable sensationalism. We have known the structure of this molecule for over a decade. And BTW, plenty of drugs have lipophilic properties. This is a bizarre and irresponsibly over-sensationalized bit...calling it an "agrochemical"...
BTW, your own malignancy event table shows a malignancy rate BELOW background rates....???
You point out that there were zero remissions the placebo arm in one of the trials in the US and call that an outlier that will concern regulators....the expected number of patients to respond in that arm per the results of the rest of the study would have been 1.6 responders on the placebo arm! 0 instead of 1...that's an anomolous signal to you?
So ultimately your bear argument is this: "This drug has NOT shown increases in cancer in patients. In fact, it has shown rates at or even BELOW the rates of other drugs approved for this disease that have no black box warning for cancer. But hey, who knows, maybe that will change someday down the road!"
BTW, you're aware there's an FDA approved AhR drug on the market already right? One with no cancer risk...
You're claiming that AhR agonism is the top secret *true* mechanism of $ABVX's obefazimod and that this is bad because you claim AhR agonism is going to cause cancer... Again, not only is the AhR agonism theory that you're treating as a revelation actually a point that $ABVX *bulls* have believed for literally years already (i.e. not news from you), but there is actually a drug ON THE MARKET today that literally has that as its exact mechanism of action...and it has no labeled risk of carcinogenicity and no studies in humans or animals supporting carcinogenic risk....So you go through all this bluster about AhR pretending it is news (it isn't) and then claiming it is going to cause cancer (even though the data we have very clearly show that it HASN'T), meanwhile, there's already been an AhR drug on the market for years that has never shown a single piece of evidence for carcinogenicity...
Like I have said in the past - I had previously agreed with some of your work. This piece is irresponsibly poorly done and the use of the word "fraud" is absolutely egregious and slanderous when your thesis ultimately boils down to..."well, they haven't shown cancer signals yet, but maybe they will someday!" Calling this fraud with the evidence you provide sincerely rises to the level of libel, in my opinion.
$ABVX Scorpion report is just silly. The entire argument is based on preclinical wet lab "research". The report makes all these outlandish claims about what the drug "might" do based on their lab work, then ignores that all of those potential "problems" have been completely debunked by ACTUAL REAL WORLD DATA.
The drug is post phase 3 already people. We already know the safety profile. The theories they published in this "short report" are *literally* the exact bear theses people were talking about 6 years ago for $ABVX. Wet lab based *theories* about the molecule itself. The difference today is that.....we literally have all the real world in human data now, AND NONE OF THOSE SCARY THEORIES TURNED OUT TO BE TRUE.
I'm with @Biohazard3737 - I increased by exposure to $ABVX this morning.
I suspect that this report coming out also explains the recent weakness in the stock. Scorpion has supposedly been working on this for 11 months. Word going around about this report is probably what caused that short report rumor and flash crash back in June too. And since then, we got EVEN MORE data proving the safety concerns are debunked. I have been baffled by even seeing the stock languishing in the $80s recently. Now I understand why that's been the case.
I've already talked to a lot of smart people on this. The near universal response is laughter/mockery. This is simply not serious work.
Congrats to Scorpion though for finding a weak stock to attack and then cover your short on a Friday Opex. $ABVX will be fine.
The thing that upsets me the most about the $ABVX short report -- beyond the timing of release coinciding on day of opex -- is that reports that go viral like this are hard to fully erase from public sentiment no matter how bogus the claims and evidence are.
2
3
392
Off-Label Trades retweeted
$ABVX
All I have to say is that if any of these was true FDA, EMA and worldwide health agencies would have placed clinical hold by now and not let trials run for 10+ years. Good luck.
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientific abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
Off-Label Trades retweeted
As a chemist who has worked on anthelmintics, this report is one of the most vulgar displays of overinterpreting LogP I think the human mind is capable of.
My guess this started w/ "Claude, is there anything weird about this molecule?"
This post deserves an award. Amazing
🚨 UPDATED FIB LEVELS FOR POPULAR STOCKS
AI Compute
• $IREN $0
• $NBIS $0
• $CIFR $0
• $DOCN $0
AI Power
• $VRT $0
• $BE $0
• $NVTS $0
• $ON $0
AI Connectivity
• $AVGO $0
• $ALAB $0
• $CRDO $0
• $MRVL $0
AI Silicon
• $NVDA $0
• $TSM $0
• $ASML $0
• $MU $0
AI Applications
• $PLTR $0
• $NOW $0
• $CRWD $0
• $SNOW $0
Physical AI
• $TSLA $0
• $AMZN $0
• $SYM $0
• $VPG $0
Drones
• $ONDS $0
• $AVAV $0
• $KTOS $0
• $MRCY $0
Quantum
• $IONQ $0
• $RGTI $0
• $QBTS $0
• $INFQ $0
Nuclear
• $OKLO $0
• $UUUU $0
• $GEV $0
• $LEU $0
Photonics
• $AAOI $0
• $COHR $0
• $VIAV $0
• $AEHR $0
CPU Bottleneck
• $AMD $0
• $INTC $0
• $ARM $0
• $AMKR $0
Space
• $RKLB $0
• $ASTS $0
• $PL $0
• $RDW $0
1
1
74
Earlier today a buyer took 151 $GPCR January 21, 2028 $22.50 calls for $67,950, with open interest at only 32 this morning.
Structure has more than halved in value since its September 8 update on aleniglipron, and its $1.2 billion market cap is now about the same as the $1.24 billion in cash it reported at September 30. Data from three smaller aleniglipron studies is due this quarter, and this buyer may be betting that's enough to win investors back well before Phase 3 results in 2028.
Someone positioning for some upwards moves?
30
Earlier today, a buyer took 180 $BEAM January 21, 2028 $10 calls at or above the ask for $228,600, with only 11 contracts open that morning so this is an opening trade. Beam reported positive pivotal risto-cel data in sickle cell disease on November 10, and the stock still sits near its 52-week low. Updated BEACON data comes at ASH on December 12, and the BLA could be filed as early as year-end.
39
Today’s biotech options flow report is up!
Daily Biotech Options Flow Report :: November 19, 2026
offlabeltrades.substack.com/…
22
If $ANT is so bullish on the future of AI making genetic diseases a thing of the past, they should just buy out $PRME already!
It is THE most programmable gene editing tech, off-targets are virtually nonexistent, and the company owns the patents that provide a strong moat against competitors in the space.
Just put in the $10-15 billion bid already and call it a day. Not even a drop in the bucket on their balance sheet, upside is huge, and in direct alignment with $ANT’s own stated goals for the future of AI in health/medicine.
What an impeccable trade. Back on Oct 27 the #1 trade I flagged in my daily report was someone paying $5.4M for 8,185 $INSM Jan $100/$130 call spreads with the stock sitting at $93.82.
With the takeover rumors this morning, $INSM is now around $138, up 47%, and that spread is fully maxed out: about $24.6M on intrinsic value, 4.5x what was paid.
Massive play, huge kudos to whoever put this one on!
1
2
258
Link to the report for those who missed it. Subscribing is free!
offlabeltrades.substack.com/…
14
For the second session running, a trader sold in-the-money $IBRX January 15 $9 puts, this time 6,000 contracts for $1.6M, after 7,750 of the same puts went for $2,247,500 yesterday. On November 9 ImmunityBio said ANKTIVA plus BCG met its primary endpoint in the BCG-naïve QUILT-2.005 trial, and it still plans to file in the fourth quarter.
1
197
I logged $123K of $IOVA June 17, 2027 $7.50 calls bought today, right at the money and filled at or above the ask, more than the 542 contracts open this morning. On November 5 Iovance said two cohorts of its registrational lung cancer trial are close to fully enrolled, with an FDA filing planned for 2027.
1
135
A day after $SLS more than doubled on its REGAL results, a buyer took $322K of the April 16 $40 calls at or above the ask, all of it a new position. SELLAS announced a $150 million stock offering that same evening and plans a BLA submission in the first half of 2027. With implied volatility at the 18th percentile, maybe this buyer saw cheap calls ahead of the filing.
138
I logged a $1.2M $CAPR bear put spread today, buying the December 18 $6 puts and selling the $2 puts against them, filled at or above the ask and 15.2 times normal size. The FDA decision on deramiocel is due Sunday, November 22, after an advisory panel voted 9 to 3 in July that the evidence didn't support a heart benefit. This trader may be betting on a rejection and a drop that lasts into December.
2
1
525
$IBRX had a large print for the second session in a row, a trader selling $1.6M of in-the-money January puts with ImmunityBio's BCG-naïve filing expected by year-end. $CAPR is back on the list too, with a $1.2M out-of-the-money December put spread placed four days before the FDA's November 22 decision on deramiocel. Further out, a buyer took out-of-the-money $KURA calls that don't expire until January 2029, which is a long time to hold a small-cap. I go through each of these in today's report. Link below, signup is free!
1
314
The full write-ups on all five trades, plus the two winners I logged today, are in the report here: offlabeltrades.substack.com/…
17
Three days before expiry, a trader opened 6,998 $ERAS November 20 $12.50/$7.50 put spreads for $419,880, at or above the ask and 22.2× normal size. Erasca holds an investor event at 8 a.m. Eastern on November 20, the morning these expire, to go over updated Phase 1 data for its pan-RAS molecular glue. Maybe the trader thinks the update falls short of what a $5.3B valuation already assumes, or it could be a hedge, tough to say.
1
136













